Gsk Plc (GSK.LN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [LSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [LSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
(Values in thousands)
| 12-2025 | 09-2025 | 06-2025 | 03-2025 | 12-2024 | |
| Cash Flows From Operating Activities | |||||
| Income taxes - deferred | 223,000 | 312,000 | 241,000 | 336,000 | 62,000 |
| Other Working Capital | 588,000 | -206,000 | -1,031,000 | -788,000 | 3,759,000 |
| Other Operating Activity | 1,467,000 | 2,116,000 | 2,886,000 | 1,597,000 | -1,492,000 |
| Operating Cash Flow | $2,278,000 | $2,222,000 | $2,096,000 | $1,145,000 | $2,329,000 |
| Cash Flows From Investing Activities | |||||
| PPE Investments | -560,000 | -306,000 | -251,000 | -207,000 | -483,000 |
| Net Acquisitions | -31,000 | -746,000 | -36,000 | -826,000 | -96,000 |
| Purchase Sale Intangibles | -449,000 | -532,000 | -377,000 | -164,000 | -586,000 |
| Other Investing Activity | 110,000 | 89,000 | 39,000 | 129,000 | 51,000 |
| Investing Cash Flow | $-933,000 | $-1,531,000 | $-625,000 | $-1,144,000 | $-1,119,000 |
| Cash Flows From Financing Activities | |||||
| Change In Short Term Borrowing | 546,000 | -89,000 | 570,000 | -100,000 | 784,000 |
| Debt Issued | 0 | -4,000 | -35,000 | 2,018,000 | 1,075,000 |
| Debt Repayment | 2,000 | 7,000 | N/A | N/A | -1,615,000 |
| Common Stock Issued | 1,000 | 0 | 2,000 | 12,000 | 0 |
| Common Stock Repurchased | -252,000 | -317,000 | -561,000 | -247,000 | N/A |
| Dividend Paid | -646,000 | -650,000 | -656,000 | -612,000 | -612,000 |
| Other Financing Activity | -507,000 | -262,000 | -1,692,000 | -213,000 | -474,000 |
| Financing Cash Flow | $-856,000 | $-1,315,000 | $-2,372,000 | $858,000 | $-842,000 |
| Exchange Rate Effect | -41,000 | 59,000 | -26,000 | -11,000 | 7,000 |
| Beginning Cash Position | 2,759,000 | 3,324,000 | 4,251,000 | 3,403,000 | 3,028,000 |
| End Cash Position | 3,207,000 | 2,759,000 | 3,324,000 | 4,251,000 | 3,403,000 |
| Net Cash Flow | $489,000 | $-624,000 | $-901,000 | $859,000 | $368,000 |
| Free Cash Flow | |||||
| Operating Cash Flow | 2,278,000 | 2,222,000 | 2,096,000 | 1,145,000 | 2,329,000 |
| Capital Expenditure | -1,025,000 | -879,000 | -633,000 | -448,000 | -1,135,000 |
| Free Cash Flow | 1,253,000 | 1,343,000 | 1,463,000 | 697,000 | 1,194,000 |